Indivior tightens grip on opioid addiction market with Sublocade's new FDA approval
The FDA has given Indivior the OK to sell its monthly injectable version of Suboxone, shoring up the company’s tenuous hold on the opioid addiction market as competition looms near.
The drug, to be marketed as Sublocade (RBP-6000), is a monthly injection of buprenorphine, which contains a mild opioid to help stymie withdrawal for addicts quitting opioid use. The medicine is meant to be used as part of a treatment plan that includes counseling and psychosocial support.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.